Feature | December 06, 2010| Dave Fornell

New Device Highlights From TCT 2010

Transcatheter valve replacement, especially transcatheter aortic valve implantation (TAVI), took center stage at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 symposium this fall in Washington, D.C. This highlights the fact the event has significantly evolved from an angioplasty meeting of 250 interventional cardiologists in the late 1980s. Today the event draws thousands of participants, including cardiac surgeons, vascular surgeons, cardiac imaging and structural heart specialists. These participants underscores a growing trend where the cath lab and its offering of minimally invasive, catheter-based procedures has expanded well beyond coronaries and into nearly all the major vessels of the body. The migration of procedures from operating rooms (ORs) to cath labs or hybrid ORs shows an increased blurring of the lines between specialities that were once silos of expertise that generally did not collaborate well.

PARTNER TAVI Results
One of the most anticipated trials at TCT 2010 was the U.S. PARTNER one-year results. The study compared outcomes of standard therapy and the Edward’s Sapien transcatheter aortic valve in patients who were considered too high-risk for surgical valve replacement. The results showed a major improvement in the transcatheter valve replacement patients. The improvements were so good, it made some experts at TCT question if it will be ethical to randomize patients in the future for standard therapy, which results in generally poor outcomes.

For more details, see the two stories on the PARTNER Trial starting on page 11. Chris S. Malaisrie, M.D., and Attapoom Susupaus, M.D., both from Northwestern University Feinberg School of Medicine, offer an update on the state of transcatheter valve technology.

Transcatheter LAA Occluders
The last issue of DAIC included a story about left atrial appendage (LAA) occlusion devices in development. The devices have the aim of replacing warfarin therapy to prevent stroke in patients with atrial fibriliation. Earlier this year, the FDA reviewed the results of the PROTECT-AF study, comparing the Watchman LAA occluder to warfarin, and decided not to clear the device for use.

Gregg Stone, M.D., New York Presbyterian Hospital, Columbia University Medical Center, speaking at a TCT 2010 session on LAA occluders, said the device shows promise, but failed to allow many patients to discontinue use of warfarin. He said the study also showed the device did not completely seal the LAA. There were also a significant number of adverse events related to implantation, which he said was due to inexperienced operators. “How are you going to become good if you only implant a device every five months?” Stone said. Complications included 30 pericardial effusions, five procedural strokes, four air embolisms, three device embolizations, 16 major bleeding events and 10 cases where surgery was needed to correct these complications.
Saibal Kar, M.D., Cedars-Sinai Medical Center, Los Angeles, said some of these complications were likely due to the Watchman’s sharp, pointed nitinol arms. He said a new device, the Coherex Wavecrest, uses rounded, loop wire arms to avoid perforations. The arms have tiny barbs to more securely anchor the device inside the appendage and avoid embolization.

The Wavecrest is covered in a PTFE (Teflon) membrane, which prevents fluid exchange between the LAA and the left atrium, unlike the net-like material used with the Watchman. This enables ultrasound blood flow imaging to ensure the device is seated properly without any major gaps.
The Wavecrest is currently in pre-clinical studies, but the company is hoping to begin first-in-man trials outside the United States by the end of 2010.

New Intravascular Imaging Modalities
Among the biggest advances on the TCT expo floor were two new FDA-cleared intravascular imaging modalities – optical coherence tomography (OCT) and intravascular ultrasound (IVUS) combined with near-infrared spectrography.

The St. Jude Medical OCT system offers a higher-resolution image than IVUS, allowing clearer evaluation of stent apposition, strut endothelialization and visualization of thrombus.

InfraRedX introduced LipiScan IVUS, which offers grayscale IVUS with a built-in, co-registered spectrograph showing the chemical make-up of plaque. It can help identify vulnerable, lipid-core plaques that are suspected of causing heart attacks and possible adverse events, such as no-flow revascularizations.

For more information on these technologies and advances in intravascular imaging, see the stories starting on page 14.

Related Content

TAVR, medical guidelines, ACC/AHA, optimization, transcatheter aortic valve replacement
News | Heart Valve Technology| January 18, 2017
The American College of Cardiology recently released new guidance for clinicians and hospitals to use in assessing...
Medtronic, CoreValve Evolut R 34 mm valve, TAVI, CE Mark, European launch
News | Heart Valve Technology| January 17, 2017
Medtronic plc announced the CE (Conformité Européenne) mark and European launch of the CoreValve Evolut R 34 mm valve...
St. Jude Medical, Amplatzer Amulet LAA Occluder, observational study, TCT 2016
News | Left Atrial Appendage (LAA) Occluders| November 03, 2016
St. Jude Medical Inc. presented favorable results from the largest observational study to date of the company’s...
Medtronic, CoreValve Evolut R TAVR system, U.S. IDE Study, TCT 2016
News | Heart Valve Technology| November 03, 2016
Medtronic plc unveiled new clinical data showing that patients treated with the self-expanding CoreValve Evolut R...
SENTINEL trial, transcatheter embolic protection, TCEP, TAVR, stroke, TCT 2016
News | Embolic Protection Devices| November 03, 2016
An international study has found that transcatheter cerebral embolic protection (TCEP) is safe, provides effective...
Medtronic, Harmony TPV, transcatheter pulmonary valve, clinical study results, TCT 2016
News | Heart Valve Technology| November 02, 2016
Medtronic plc recently announced new clinical data for the Harmony Transcatheter Pulmonary Valve (TPV) from its early...
Edwards, Sapien transcatheter heart valve, PARTNER trial, five-year echo data, TCT 2016
News | Heart Valve Technology| November 01, 2016
Edwards Lifesciences Corp. announced new five-year hemodynamic data from the PARTNER Trial demonstrating excellent...
Medtronic, CoreValve Evolut R TAVR system, TCT 2016, FORWARD Study, STS/ACC TVT Registry
News | Heart Valve Technology| October 31, 2016
Medtronic plc presented new positive data from two large registries aimed at evaluating 30-day clinical performance...
OCT, optical coherence tomography, coronary stent implantation, superior resolution, TCT 2016, ILLUMIEN III OPTIMIZE PCI Trial
News | Optical Coherence Tomography (OCT)| October 31, 2016
Optical coherence tomography (OCT) provides safe and improved guidance for patients undergoing percutaneous coronary...
Mitralign, Trialign tricuspid repair system, SCOUT I study, 30-day data, TCT 2016
News | Heart Valve Technology| October 28, 2016
Mitralign will present data on its Trialign Tricuspid Repair system at the 2016 Transcatheter Cardiovascular...
Overlay Init